Jazz Pharmaceuticals plc Cash and Restricted Cash
Jazz Pharmaceuticals plc (JAZZ) had Cash and Restricted Cash of $1.62 billion as of 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-03
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $1.62B.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $1.84B.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $1.39B; Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents as first filed $1.39B.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $1.33B.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents as first filed |
|---|---|---|
| 2026-06-30 | $1.62B 10-Q · filed 2026-08-03 | |
| 2026-03-31 | $1.84B 10-Q · filed 2026-05-05 | |
| 2025-12-31 | $1.39B 10-Q · filed 2026-08-03 | $1.39B 10-K · filed 2026-02-24 |
| 2025-09-30 | $1.33B 10-Q · filed 2025-11-05 | |
| 2025-06-30 | $1.19B 10-Q · filed 2026-08-03 | $1.19B 10-Q · filed 2025-08-06 |
| 2025-03-31 | $1.86B 10-Q · filed 2026-05-05 | $1.86B 10-Q · filed 2025-05-07 |
| 2024-12-31 | $2.41B 10-Q · filed 2026-08-03 | $2.41B 10-K · filed 2025-02-26 |
| 2024-09-30 | $2.22B 10-Q · filed 2025-11-05 | |
| 2024-06-30 | $1.36B 10-Q · filed 2025-08-06 | |
| 2024-03-31 | $1.44B 10-Q · filed 2025-05-07 | |
| 2023-12-31 | $1.51B 10-K · filed 2026-02-24 | |
| 2023-09-30 | $1.34B 10-Q · filed 2024-11-07 | |
| 2023-06-30 | $1.28B 10-Q · filed 2024-08-01 | |
| 2023-03-31 | $1.17B 10-Q · filed 2024-05-02 | |
| 2022-12-31 | $881.48M 10-K · filed 2026-02-24 | |
| 2022-09-30 | $839.36M 10-Q · filed 2023-11-08 | |
| 2022-06-30 | $711.26M 10-Q · filed 2023-08-09 | |
| 2022-03-31 | $490.83M 10-Q · filed 2023-05-10 | |
| 2021-12-31 | $591.45M 10-K · filed 2025-02-26 | |
| 2021-09-30 | $671.78M 10-Q · filed 2022-11-09 | |
| 2021-06-30 | $891.40M 10-Q · filed 2022-08-03 | |
| 2021-03-31 | $2.10B 10-Q · filed 2022-05-04 | |
| 2020-12-31 | $1.06B 10-K · filed 2024-02-28 | |
| 2020-09-30 | $741.94M 10-Q · filed 2021-11-09 | |
| 2020-06-30 | $786.08M 10-Q · filed 2021-08-03 | |
| 2020-03-31 | $701.60M 10-Q · filed 2021-05-04 | |
| 2019-12-31 | $637.34M 10-K · filed 2023-03-01 | |
| 2019-09-30 | $795.17M 10-Q · filed 2020-11-02 | |
| 2019-06-30 | $637.74M 10-Q · filed 2020-08-04 | |
| 2019-03-31 | $547.47M 10-Q · filed 2020-05-05 | |
| 2018-12-31 | $309.62M 10-K · filed 2022-03-01 | |
| 2018-09-30 | $499.02M 10-Q · filed 2019-11-05 | |
| 2018-06-30 | $485.08M 10-Q · filed 2019-08-06 | |
| 2018-03-31 | $453.17M 10-Q · filed 2019-05-07 | |
| 2017-12-31 | $386.04M 10-K · filed 2021-02-23 | |
| 2016-12-31 | $365.96M 10-K · filed 2020-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |